


PRODUCT INFORMATION



Benzarone

Item No. 34903

CAS Registry No.: 1477-19-6
Formal Name: (2-ethyl-3-benzofuranyl)
(4-hydroxyphenyl)-methanone
Synonyms: L 2197, NSC 82134
MF: C₁₇H₁₄O₃
FW: 266.3
Purity: ≥98%
UV/Vis.: λ_{max}: 231, 284 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Benzarone is supplied as a solid. A stock solution may be made by dissolving the benzarone in the solvent of choice, which should be purged with an inert gas. Benzarone is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of benzarone in ethanol and DMSO is approximately 10 mg/ml and approximately 30 mg/ml in DMF.

Description

Benzarone is an active metabolite of the urate anion transporter 1 (URAT1) inhibitor benzobromarone (Item No. 19768).^{1,2} It inhibits URAT1 in *Xenopus* oocytes expressing the human enzyme (IC₅₀ = 2.8 μM).² Benzarone also inhibits the tyrosine phosphatase activity of eyes absent homolog 3 (EYA3; IC₅₀ = 17.5 μM), as well as reduces the proliferation and migration of human umbilical vein endothelial cells (HUVECs) when used at a concentration of 7.5 μM.³ It uncouples oxidative phosphorylation in isolated rat liver mitochondria and induces apoptosis and necrosis in isolated rat hepatocytes.⁴ Benzarone (25 μg/g) reduces tumor growth in an A-673 Ewing sarcoma mouse xenograft model.⁵

References

1. Stüber, W. and Möller, H. Determination of benzobromarone, bromobenzarone and benzarone in plasma by gas chromatography–mass spectrometry. *J. Chromatogr. B Biomed. Sci. Appl.* **224(2)**, 327-331 (1981).
2. Wempe, M.F., Jutabha, P., Quade, B., et al. Developing potent human uric acid transporter 1 (hURAT1) inhibitors. *J. Med. Chem.* **54(8)**, 2701-2713 (2011).
3. Pandey, R.N., Wang, T.S., Tadjuidje, E., et al. Structure-activity relationships of benzobromarone metabolites and derivatives as EYA inhibitory anti-angiogenic agents. *PLoS One* **8(12)**, e84582 (2013).
4. Kaufmann, P., Török, M., Hänni, A., et al. Mechanisms of benzarone and benzobromarone-induced hepatic toxicity. *Hepatology* **41(4)**, 925-935 (2005).
5. Wang, Y., Pandey, R.N., Roychoudhury, K., et al. Targeting EYA3 in ewing sarcoma retards tumor growth and angiogenesis. *Mol. Cancer Ther.* **20(5)**, 803-815 (2021).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/07/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM